Israel’s Pluristem Therapeutics (reported here previously) has been approved by German’s health regulatory authority to conduct a Phase 2 clinical trial of its PLX PAD stem cells on 40 serious Covid-19 patients. Pluristem is already conducting a 140-patient Phase 2 trial in the US.

https://www.pluristem.com/wp-content/uploads/2020/08/PEI-Clearance-to-Commence-Phase-II-Study-in-Germany-FINAL-FOR-RELEASE.pdf